Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-06-28 1:51 pm Sale | 13D | CTI BIOPHARMA CORP CTIC | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -28,463,021 (Position Closed) | View |
| 2023-04-14 08:25 am Purchase | 13G | CTI BIOPHARMA CORP CTIC | Stonepine Capital Management LLC | 7,018,046 5.3% | 1,353,946 (+23.90%) | View |
| 2023-03-24 4:49 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | LYNCH TIMOTHY P | 6,999,275 5.3% | 6,999,275 (New Position) | View |
| 2023-02-13 10:27 am Sale | 13G | CTI BIOPHARMA CORP CTIC | Stonepine Capital Management LLC | 5,664,100 4.5% | -4,090,835 (-41.94%) | View |
| 2023-02-03 4:04 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | STATE STREET CORP STT | 16,002,989 12.61% | 2,260,435 (+16.45%) | View |
| 2023-02-03 12:10 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | BlackRock Inc. BLK | 7,060,319 5.6% | 7,060,319 (New Position) | View |
| 2023-01-09 4:31 pm Sale | 13G | CTI BIOPHARMA CORP CTIC | MILLENNIUM MANAGEMENT LLC | 4,962,769 3.9% | -979,516 (-16.48%) | View |
| 2022-10-11 2:01 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | STATE STREET CORP STT | 13,742,554 12.01% | 13,742,554 (New Position) | View |
| 2022-08-11 4:48 pm Purchase | 13D | CTI BIOPHARMA CORP CTIC | BIOTECHNOLOGY VALUE FUND L P | 28,463,021 19.99% | 11,339,998 (+66.23%) | View |
| 2022-07-22 4:06 pm Sale | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 0 0% | -9,613,101 (Position Closed) | View |
| 2022-06-17 5:10 pm Purchase | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 9,613,101 8.8% | 2,228,285 (+30.17%) | View |
| 2022-06-13 4:36 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | MILLENNIUM MANAGEMENT LLC | 5,942,285 5.5% | 5,942,285 (New Position) | View |
| 2022-02-14 4:01 pm Sale | 13G | CTI BIOPHARMA CORP CTIC | CAXTON CORP | 2,239,300 2.3% | -1,510,590 (-40.28%) | View |
| 2022-02-11 7:06 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | Stonepine Capital Management LLC | 9,754,935 9.99% | 1,606,515 (+19.72%) | View |
| 2021-12-06 4:25 pm Sale | 13G | CTI BIOPHARMA CORP CTIC | ORBIMED ADVISORS LLC | 4,024,821 4% | -5,495,179 (-57.72%) | View |
| 2021-03-15 07:55 am Purchase | 13D | CTI BIOPHARMA CORP CTIC | BIOTECHNOLOGY VALUE FUND L P | 17,123,023 19.99% | 4,369,333 (+34.26%) | View |
| 2021-02-16 4:23 pm Sale | 13G | CTI BIOPHARMA CORP CTIC | CAXTON CORP | 3,749,890 5.1% | -737,427 (-16.43%) | View |
| 2021-02-12 4:26 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | Stonepine Capital Management LLC | 8,148,420 9.99% | 4,534,820 (+125.49%) | View |
| 2020-10-01 5:55 pm Purchase | 13G | CTI BIOPHARMA CORP CTIC | CAXTON CORP | 4,487,317 6.1% | 4,487,317 (New Position) | View |
| 2020-03-12 08:03 am Purchase | 13D | CTI BIOPHARMA CORP CTIC | Growth Equity Opportunities V LLC | 7,384,816 9.99% | 3,634,816 (+96.93%) | View |